文献速递妇科产科

阴道网片与腹腔镜网片骶骨固定术治疗膀胱膨出四年结局

Long-term outcomes of primary cystocele repair by transvaginal mesh surgery versus laparoscopic mesh sacropexy: extended follow up of the PROSPERE multicentre randomised trial.
PubMed 文献 · BJOG · 2021-08-05

PROSPERE多中心随机试验的4年扩展随访,比较腹腔镜骶骨固定术(LS)与经阴道网片(TVM)治疗膀胱膨出≥2期、45-75岁无既往脱垂手术女性的效果与安全性。主要功能结局PFDI-20在LS组略优但低于最小临床重要差异;两组成功率相似;LS组III级及以上并发症更少。

要点

  • LS与TVM术后4年成功率相似,功能与解剖改善均持续。
  • LS组PFDI-20略优,但差异未达最小临床重要差异。
  • LS组III级及以上并发症及因并发症再干预更少。

核心结论

  • 两种术式均改善症状且成功率相似,LS获益-风险平衡更优,TVM在LS不可行时仍为选择。

研究设计与样本

  • 纳入膀胱膨出POP-Q≥2期、45-75岁、无既往脱垂手术女性。
  • LS组将合成不可吸收网片置于膀胱阴道间隙并固定于骶骨岬;TVM组网片经臂固定于盆腔韧带和/或肌肉。

主要发现

  • PFDI-20两组均显著改善,LS组平均差异-7.2分(95%CI -14.0至-0.05,P=0.029),低于最小临床重要差异。
  • 成功率LS 70%(61-81%)与TVM 71%(62-81%)相似,风险比0.92(95%CI 0.55-1.54,P=0.75)。
  • POP-Q除C点外无差异,C点LS -57 mm vs TVM -48 mm(P=0.0093)。
  • III级及以上并发症LS 2%(0-4.7%)低于TVM 8.7%(3.4-13.7%),风险比4.6(95%CI 1.007-21.0,P=0.049)。

关键数值与推荐

  • 主要结局为PFDI-20功能结局;成功率采用复合结局。
  • LS组III级及以上并发症率2%(0-4.7%),TVM组8.7%(3.4-13.7%)。

临床怎么用

  • LS可作为膀胱膨出修补优先术式,因获益-风险平衡更优且并发症再干预更少。
  • TVM在LS不可行时仍为可选方案。

局限性

  • 4年随访完成220/262例,存在失访。
  • 部分比较的置信区间较宽,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the effectiveness and safety of laparoscopic sacropexy (LS) and transvaginal mesh (TVM) at 4 years. DESIGN: Extended follow up of a randomised trial. SETTING: Eleven centres. POPULATION: Women with cystocele stage ≥2 (pelvic organ prolapse quantification [POP-Q], aged 45-75 years without previous prolapse surgery. METHODS: Synthetic non-absorbable mesh placed in the vesicovaginal space and sutured to the promontory (LS) or maintained by arms through pelvic ligaments and/or muscles (TVM). MAIN OUTCOME MEASURES: Functional outcomes (pelvic floor distress inventory [PFDI-20] as primary outcome); anatomical assessment (POP-Q), composite outcome of success; re-interventions for complications. RESULTS: A total of 220 out of 262 randomised patients have been followed at 4 years. PFDI-20 significantly improved in both groups and was better (but below the minimal clinically important difference) after LS (mean difference -7.2 points; 95% CI -14.0 to -0.05; P = 0.029). The improvement in quality of life and the success rate (LS 70%, 61-81% versus TVM 71%, 62-81%; hazard ratio 0.92, 95% CI 0.55-1.54; P = 0.75) were similar. POP-Q measurements did not differ, except for point C (LS -57 mm versus TVM -48 mm, P = 0.0093). The grade III or higher complication rate was lower after LS (2%, 0-4.7%) than after TVM (8.7%, 3.4-13.7%; hazard ratio 4.6, 95% CI 1.007-21.0, P = 0.049)). CONCLUSIONS: Both techniques provided improvement and similar success rates. LS had a better benefit-harm balance with fewer re-interventions due to complications. TVM remains an option when LS is not feasible. TWEETABLE ABSTRACT: At 4 years, Laparoscopic Sacropexy (LS) had a better benefit-harm balance with fewer re-interventions due to complications than Trans-Vaginal Mesh (TVM).

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lucot JP, Cosson M, Verdun S, et al. Long-term outcomes of primary cystocele repair by transvaginal mesh surgery versus laparoscopic mesh sacropexy: extended follow up of the PROSPERE multicentre randomised trial. BJOG. 2021. PMID: 34264001. doi:10.1111/1471-0528.16847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。